MiMedx Group マネジメント
マネジメント 基準チェック /24
MiMedx Groupの CEO はJoe Capperで、 Jan2023年に任命され、 の在任期間は 3.33年です。 の年間総報酬は$ 7.18Mで、 10.7%給与と89.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.36%を直接所有しており、その価値は$ 2.01M 。経営陣と取締役会の平均在任期間はそれぞれ3.3年と5.8年です。
主要情報
Joe Capper
最高経営責任者
US$7.2m
報酬総額
| CEO給与比率 | 10.70% |
| CEO在任期間 | 3.3yrs |
| CEOの所有権 | 0.4% |
| 経営陣の平均在職期間 | 3.3yrs |
| 取締役会の平均在任期間 | 5.8yrs |
経営陣の近況
Recent updates
Seeking Alpha • May 09
MiMedx: The Hard Math Behind My Downgrade To Hold
Summary MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited. Management targets breakeven in Q3 via $40 million cost cuts, but execution risk remains high amid industry 'fire sale' conditions and uncertain wound care recovery. Read the full article on Seeking Alpha
ナラティブの更新 • May 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price targets on MiMedx Group by several dollars to reflect lower fair value estimates, softer revenue and margin assumptions, and a higher implied future P/E, as highlighted in recent research updates from multiple firms. Analyst Commentary Recent research on MiMedx Group highlights a mixed set of views, with several firms lowering price targets while still pointing to specific factors that could support value over time.
新しいナラティブ • May 03
Surgical Adoption And Cost Cuts Will Reshape Long Term Potential For This Biologics Supplier
Catalysts About MiMedx Group MiMedx Group develops and markets placental tissue and related biologic products for wound care and surgical applications. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Apr 20
MDXG: Medicare Policy Reset Will Support Chronic Wound Biologics Recovery Narrative
Analysts have trimmed the average price target for MiMedx Group from about $9.67 to $8.20, citing updated assumptions for revenue growth, profit margins, and a higher future P/E following a series of recent target cuts across the Street. Analyst Commentary Recent Street research on MiMedx Group centers on how Medicare reimbursement decisions and updated modeling are feeding into price targets, ratings, and expectations for future execution.
新しいナラティブ • Apr 18
Reimbursement And Competition Will Pressure Margins Yet Long Term Surgical Demand Will Support Upside
Catalysts About MiMedx Group MiMedx Group develops and commercializes human placental tissue and complementary products for Wound Care and Surgical applications. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Apr 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Recovery Narrative
The consolidated analyst price target for MiMedx Group now reflects a modest adjustment of cents per share, as analysts weigh ongoing Medicare reimbursement changes and recent coverage initiations that highlight both prior headwinds and the potential for a rebound in chronic wound biologics. Analyst Commentary Recent research updates show a mix of optimism and caution around MiMedx Group, with views largely shaped by Medicare reimbursement shifts and how these might influence the value investors place on the chronic wound biologics portfolio.ナラティブの更新 • Mar 22
MDXG: CMS Reimbursement Reset Will Set Up Biologics Comeback Narrative
Analysts have adjusted their MiMedx Group price targets, with recent moves ranging from $8 to $10 per share as they factor in shifting Medicare reimbursement developments and a potential recovery from prior headwinds. Analyst Commentary Recent research on MiMedx Group reflects a mix of optimism about potential recovery and caution around reimbursement and execution risk, which feeds directly into the range of price targets between $8 and $10 per share.ナラティブの更新 • Mar 07
MDXG: Wound Care Expansion And CMS Reset Will Support Future Rebound
The analyst price target for MiMedx Group has shifted modestly to about $9.67 per share, as analysts factor in recent reimbursement headwinds that weighed on the stock, while still noting potential upside with fresh targets such as $10 from new coverage and $8 from revised models. Analyst Commentary Recent research updates around MiMedx highlight a mix of optimism about the core wound care franchise and caution around reimbursement uncertainty and valuation reset.ナラティブの更新 • Feb 21
MDXG: Wound Care Portfolio Expansion Will Offset CMS Reimbursement Uncertainty
Analysts have trimmed their price targets on MiMedx Group, with one key target moving from $12 to $8, as they revisit growth, margin and P/E assumptions following recent CMS related reimbursement updates. Analyst Commentary Recent research updates point to a reset in expectations for MiMedx Group, as analysts update their models following the CMS reimbursement developments and pull back their price targets.ナラティブの更新 • Feb 06
MDXG: Wound Care Portfolio Expansion Will Drive Future Upside Potential
Analysts have reduced their price target on MiMedx Group to about US$10.40 from roughly US$11.00. This change reflects slightly more cautious assumptions on fair value, revenue growth, profit margins, and future P/E multiples following recent research updates.ナラティブの更新 • Jan 22
MDXG: Execution On Wound Care Expansion Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for MiMedx Group from US$12.20 to US$11.00, citing updated assumptions around discount rates, revenue growth, margins, and future P/E multiples as the key drivers behind the change. Analyst Commentary Recent Street research includes lower price targets from different firms that both bring MiMedx Group’s fair value range closer to the updated estimate.分析記事 • Jan 09
Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...分析記事 • Nov 06
MiMedx Group's (NASDAQ:MDXG) Soft Earnings Don't Show The Whole Picture
MiMedx Group, Inc.'s ( NASDAQ:MDXG ) stock was strong despite it releasing a soft earnings report last week. We think...分析記事 • Jul 04
MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Apr 17
Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...分析記事 • Mar 27
MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...分析記事 • Mar 05
Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings
The market was pleased with the recent earnings report from MiMedx Group, Inc. ( NASDAQ:MDXG ), despite the profit...分析記事 • Feb 22
Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...分析記事 • Dec 23
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Nov 21
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...分析記事 • Nov 06
There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
MiMedx Group, Inc. ( NASDAQ:MDXG ) shares have had a really impressive month, gaining 27% after a shaky period...
新しいナラティブ • Sep 24
HELIOGEN's Launch And Scientific Breakthroughs Promise Growth Amid Reimbursement And Legal Challenges
The launch of HELIOGEN and strategic expansions in the surgical market underscore innovation and efforts to boost revenue through new market penetration and customer loyalty.分析記事 • May 21
MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry
MiMedx Group, Inc. ( NASDAQ:MDXG ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...分析記事 • May 14
We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$31m |
| Dec 31 2025 | US$7m | US$768k | US$49m |
| Sep 30 2025 | n/a | n/a | US$41m |
| Jun 30 2025 | n/a | n/a | US$32m |
| Mar 31 2025 | n/a | n/a | US$40m |
| Dec 31 2024 | US$1m | US$750k | US$42m |
| Sep 30 2024 | n/a | n/a | US$79m |
| Jun 30 2024 | n/a | n/a | US$79m |
| Mar 31 2024 | n/a | n/a | US$68m |
| Dec 31 2023 | US$21m | US$678k | US$56m |
報酬と市場: Joeの 総報酬 ($USD 7.18M ) は、 US市場 ($USD 2.67M ) の同規模の企業の平均を上回っています。
報酬と収益: Joeの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。
CEO
Joe Capper (61 yo)
3.3yrs
在職期間
US$7,182,208
報酬
Mr. Joseph H. Capper, also known as Joe, is an Independent Director at Anika Therapeutics, Inc since May 28, 2024. He serves as Chief Executive Officer and Director of MiMedx Group, Inc. since January 30,...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 3.3yrs | US$7.18m | 0.36% $ 2.0m | |
| Chief Financial Officer | 2.8yrs | US$2.12m | 0.14% $ 763.1k | |
| General Counsel & Chief Administrative Officer | 6.4yrs | US$2.15m | 0.24% $ 1.4m | |
| Chief Commercial Officer | 1.9yrs | US$2.06m | 0.034% $ 194.4k | |
| SVP of R&D & Medical Affairs and Chief Scientific Officer | no data | データなし | データなし | |
| Head of Investor Relations | 3.6yrs | データなし | データなし | |
| Senior VP & Chief Compliance Officer | 3.1yrs | データなし | データなし | |
| Vice President of Investor Relations & Corporate Strategic Communications | no data | データなし | データなし | |
| Senior VP of Marketing & International | 3.3yrs | データなし | データなし | |
| Chief Human Resources Officer | less than a year | データなし | データなし | |
| Chief Medical Officer | 7.4yrs | データなし | データなし | |
| President of Regenerative Medicine & Biologics Innovation | 5.8yrs | US$1.74m | データなし |
3.3yrs
平均在職期間
59yo
平均年齢
経験豊富な経営陣: MDXGの経営陣は 経験豊富 であると考えられます ( 3.3年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 3.3yrs | US$7.18m | 0.36% $ 2.0m | |
| Independent Preferred Director | 5.8yrs | データなし | 0.00034% $ 1.9k | |
| Independent Director | 6.9yrs | US$237.72k | 0.12% $ 698.0k | |
| Independent Preferred Director | 5.8yrs | US$226.75k | 0.12% $ 664.8k | |
| Member of Medical Advisory Board | no data | データなし | データなし | |
| Independent Director | no data | US$301.78k | 0.12% $ 698.0k | |
| Member of Medical Advisory Board | no data | データなし | データなし | |
| Independent Director | 5.5yrs | US$227.03k | 0.10% $ 581.0k | |
| Independent Director | 6.9yrs | US$235.58k | 0.24% $ 1.4m | |
| Member of Regenerative Medicine Scientific Advisory Board | no data | データなし | データなし | |
| Member of Medical Advisory Board | no data | データなし | データなし | |
| Member of Regenerative Medicine Scientific Advisory Board | 3.8yrs | データなし | データなし |
5.8yrs
平均在職期間
70.5yo
平均年齢
経験豊富なボード: MDXGの 取締役会 は 経験豊富 であると考えられます ( 5.8年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 07:36 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
MiMedx Group, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11
| アナリスト | 機関 |
|---|---|
| William Plovanic | Canaccord Genuity |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |